Pulmonary hypertension in patients with amyloidosis.

Pulmonary hypertension (PH) with right-sided cardiac failure is a rare complication of amyloidosis, and its natural history is not well-defined. The aim of our study was to evaluate patients who were seen at our institution who had PH and amyloidosis and to describe the natural history of this complication. The study was a retrospective chart review of patients seen at the Mayo Clinic with both PH and amyloidosis listed as major diagnoses between January 1, 1980, and December 31, 1999. Patients with known causes of PH were excluded. Five patients met our criteria (four women and one man). Four patients had light-chain amyloidosis and one had amyloid A deposition secondary to familial Mediterranean fever. All patients had symptoms related to PH without echocardiographic evidence of left ventricular dysfunction. The median survival time after the diagnosis of amyloidosis was 2.8 years, and PH was found a median of 73 days before death. Five patients died of cardiac complications, including one with sudden cardiac death. PH is an unusual complication of amyloidosis. Patients develop PH late in the disease process and do not have a worse prognosis compared to other patients with cardiac amyloidosis. PH is a marker of advanced amyloidosis.

[1]  W. Edwards,et al.  Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. , 2000, The American journal of medicine.

[2]  M. Krowka Pulmonary hypertension: diagnostics and therapeutics. , 2000, Mayo Clinic proceedings.

[3]  R. Cannon,et al.  Systemic Amyloidosis Presenting with Angina Pectoris , 1999, Annals of Internal Medicine.

[4]  J. Loscalzo,et al.  Prothrombotic mechanisms in primary pulmonary hypertension. , 1999, The Journal of laboratory and clinical medicine.

[5]  K. Kerr,et al.  Right Heart Failure as the Dominant Clinical Picture in a Case of Primary Amyloidosis Affecting the Pulmonary Vasculature , 1999, Scottish medical journal.

[6]  A. Dispenzieri,et al.  Amyloidosis: recognition, confirmation, prognosis, and therapy. , 1999, Mayo Clinic proceedings.

[7]  R. D. Murray,et al.  Duration of pulmonary venous atrial reversal flow velocity and mitral inflow a wave: new measure of severity of cardiac amyloidosis. , 1998, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[8]  A. Fishman Etiology and pathogenesis of primary pulmonary hypertension: a perspective. , 1998, Chest.

[9]  M. Mullan,et al.  Characteristics of thein VitroVasoactivity of β-Amyloid Peptides , 1998, Experimental Neurology.

[10]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[11]  A. Tajik,et al.  Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy. , 1997, The American journal of cardiology.

[12]  À. Argilés β2‐Microglobulin amyloidosis , 1996 .

[13]  W. Edwards,et al.  The premortem recognition of systemic senile amyloidosis with cardiac involvement. , 1996 .

[14]  S. Swensen,et al.  Pulmonary Amyloidosis. The Mayo Clinic Experience from 1980 to 1993 , 1996, Annals of Internal Medicine.

[15]  K. Koch,et al.  Right ventricular cardiac failure and pulmonary hypertension in a long-term dialysis patient--unusual presentation of visceral beta 2-microglobulin amyloidosis. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  W. Edwards,et al.  Pulmonary vascular amyloid causing pulmonary hypertension: Report of a case and review of literature , 1993 .

[17]  W. J. Johnson,et al.  Pulmonary hypertension and familial Mediterranean fever: a previously unrecognized association. , 1991, Mayo Clinic proceedings.

[18]  A J Tajik,et al.  Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. , 1990, Journal of the American College of Cardiology.

[19]  J. Seward,et al.  Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. , 1989, Journal of the American College of Cardiology.

[20]  D. McNally,et al.  Pulmonary hypertension from prominent vascular involvement in diffuse amyloidosis. , 1988, Archives of internal medicine.

[21]  J. Seward,et al.  Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. , 1985, Journal of the American College of Cardiology.

[22]  R. Falk,et al.  Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. , 1985, The American journal of cardiology.